Table 3.
Treatment-Related Toxicities
| Toxicity | No. of Patients
|
|||||
|---|---|---|---|---|---|---|
| 150 PRE
|
1,500 PRE
|
1,500 POST
|
||||
| Grade 3 | Grade 4 | Grade 3 | Grade 4 | Grade 3 | Grade 4 | |
| Neutropenia | 4 | 5 | 6 | 9 | 3 | 8 |
| Anemia | 2 | 0 | 0 | 0 | 2 | 0 |
| Thrombocytopenia | 0 | 2 | 1 | 1 | 0 | 0 |
| Neuropathy | 1 | 0 | 3 | 0 | 1 | 0 |
| Thrombosis | 2 | 1 | 2 | 0 | 2 | 0 |
| Fatigue | 2 | 1 | 3 | 0 | 4 | 0 |
| Dyspnea | 2 | 1 | 2 | 0 | 2 | 0 |
Abbreviations: 150 PRE, erlotinib 150 mg on days 1 and 2 followed by chemotherapy on day 3; 1,500 PRE, erlotinib 1,500 mg on days 1 and 2 followed by chemotherapy on day 3; 1,500 POST, chemotherapy on day 1 followed by erlotinib 1,500 mg on days 2 and 3.